176 related articles for article (PubMed ID: 28273376)
1. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.
Aurich S; Simon JC; Treudler R
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e395-e397. PubMed ID: 28273376
[No Abstract] [Full Text] [Related]
2. A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab.
Nucera E; Basta F; Buonomo A; Mezzacappa S; Margiotta DP; Antonelli Incalzi R; Schiavino D
J Investig Allergol Clin Immunol; 2017; 27(6):382-384. PubMed ID: 29199964
[No Abstract] [Full Text] [Related]
3. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration.
Ito T; Maeda T; Egusa C; Abe N; Seshimo H; Okubo Y; Harada K
Allergol Int; 2021 Apr; 70(2):269-270. PubMed ID: 33183981
[No Abstract] [Full Text] [Related]
4. Successful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report.
Pérez Codesido S; Rosado Ingelmo A; Gómez de la Fuente E; García García E; Privitera Torres M; Tejedor Alonso MA
J Investig Allergol Clin Immunol; 2020 Jun; 30(3):211-212. PubMed ID: 32571766
[No Abstract] [Full Text] [Related]
5. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
Baldallo C; León Román JC; Serón D; Agraz I; Solans R; Ramos N; Soler MJ
Nefrologia (Engl Ed); 2021; 41(3):354-356. PubMed ID: 32826086
[No Abstract] [Full Text] [Related]
7. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis.
Navarro-Navarro I; Jiménez-Gallo D; Villegas-Romero I; Linares-Barrios M
Dermatol Ther; 2020 Mar; 33(2):e13237. PubMed ID: 32012397
[No Abstract] [Full Text] [Related]
8. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
Kai AC; Flohr C; Grattan CE
Clin Exp Dermatol; 2014 Jul; 39(5):651-2. PubMed ID: 24758481
[No Abstract] [Full Text] [Related]
9. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of refractory cholinergic urticaria with omalizumab.
Koumaki D; Seaton ED
Int J Dermatol; 2018 Jan; 57(1):114. PubMed ID: 29057464
[No Abstract] [Full Text] [Related]
11. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
Baldallo C; León Román JC; Seron D; Agraz I; Solans R; Ramos N; Soler MJ
Nefrologia (Engl Ed); 2021; 41(3):354-355. PubMed ID: 36166252
[No Abstract] [Full Text] [Related]
12. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy.
Ensina LF; Cusato-Ensina AP; Camelo-Nunes IC; Solé D
J Investig Allergol Clin Immunol; 2017; 27(5):326-327. PubMed ID: 29057743
[No Abstract] [Full Text] [Related]
13. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
Rattananukrom T; Svetvilas P; Chanprapaph K
Asian Pac J Allergy Immunol; 2020 Dec; 38(4):286-289. PubMed ID: 30660172
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory myositis complicating hypocomplementemic urticarial vasculitis despite on-going immunosuppression.
Chew GY; Gatenby PA
Clin Rheumatol; 2007 Aug; 26(8):1370-2. PubMed ID: 16944070
[TBL] [Abstract][Full Text] [Related]
15. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine.
Lopez LR; Davis KC; Kohler PF; Schocket AL
J Allergy Clin Immunol; 1984 May; 73(5 Pt 1):600-3. PubMed ID: 6371104
[TBL] [Abstract][Full Text] [Related]
16. Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone.
Fortson JS; Zone JJ; Hammond ME; Groggel GC
J Am Acad Dermatol; 1986 Nov; 15(5 Pt 2):1137-42. PubMed ID: 3771868
[TBL] [Abstract][Full Text] [Related]
17. Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints.
Kutlu A; Tanoglu A; Ozturk S
Chin Med J (Engl); 2015 Jun; 128(11):1559-60. PubMed ID: 26021519
[No Abstract] [Full Text] [Related]
18. Chronic Idiopathic Urticaria.
Wu EY; Saini SS
J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
[No Abstract] [Full Text] [Related]
19. Effectiveness of omalizumab in severe solar urticaria.
de Dios-Velázquez Á; González-de Arriba M; Beteta-Gorriti V; Macías E; Campanón-Toro V; Dávila I
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):260-2. PubMed ID: 26803538
[No Abstract] [Full Text] [Related]
20. Dermatologic uses of omalizumabtitle.
Chia JC; Mydlarski PR
J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
